share_log

HC Wainwright & Co. Maintains Buy on Gain Therapeutics, Lowers Price Target to $9

Benzinga ·  Dec 4, 2023 06:47

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and lowers the price target from $10 to $9.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment